Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Oct
18
Today In Oncology
Verifying the Seen and Unseen by AI in Cancer Imaging
AI-Extracted Chart Data for Expanding Surgical Oncology Learnings
Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo